Merseyside & Cheshire

See the projects that we're currently funding in your region.

The cellular response to DNA damage: Ubiquitylation-dependant regulation of 8-oxoguanine DNA glycosylase (OGGI)

Dr Parsons          £114,670 / three years 

 

Characterisation of the endothelial cell surface molecule(s) responsible for galectin -3- induced secretion of metastasis-promoting cytokine

Dr Lu-Gang Yu, Prof Rhoses, Prof Beynon           £149,811 / three years 

 

The KRAS regulated kinase, DCLK1: downstream elements and their roles in cancer

Prof Clague, Prof Urbe          £185,303 /  three years 

 

Analysis of MAP4K3 function and regulation in cancer

Dr Lamb, Dr Eyers               £122,262

 

A phase lb study of pre-operative cisplatin and gemcitabine chemotherapy in patients with Borderline resectable Biliary tract cancer: BBC-01 study

Prof Palmer, Mr Jones, Mr Malik          £119,657

 

Determining ibrutinib’s potential to treat human leukaemias – novel uses for an exciting new Bruton’s tyrosine kinase (BTK) inhibitor

Prof MacEwan, Prof Pettitt, Dr Slupsky           £162,443 / three years 

 

Molecular mechanism of regulation of the cellular protein levels of endonuclease III homologue (NTH1), in response to DNA damage

Dr Parsons           £113,754 / three years 

 

Myofibroblast control of oesophageal squamous cancer invasion: role of chemerin

Prof Varro, Prof Beynon, Prof Dockray           £114,975 / two years 

 

Why are Ras isoforms not redundant? Characterising isoform-specific oncogenic Ras signalling networks

Prof Prior           £194,803 / three years 

 

Regulation of actin mediated endocytic recycling in invasive Her2 positive breast cancer

Dr Zech            £190,962 / three years 

 

Functional characterisation of the distinct complexes of MCL-1, an anti-apoptotic BCL-2 family member, in regulating apoptosis in cancer cells

Dr Varadarajan, Prof Cohen          £134,689 / three years 

 

Characterising the Bruton’s tyrosine kinase signalling nexus in leukaemia

Dr Slupsky, Prof Prior, Prof MacEwan          £185,950 / three years  

 

Optimising NK cell cytotoxicity and infiltration and global health

Dr Coombes, Dr Morgan             £133,823 / three years 

 

Targeting an Achilles’ heel of cancer: Debiquitylases as novel targets for centrosome decluttering and cancer-cell specific death

Dr Coulson          £189,049 / three years 

 

The NWCR Bioinformatics Fellowship

Dr Hammond      £176,632 / three years 

 

Exosome biogenesis: the role of sortilin in cancer biology

Dr Liloglou, Dr Wilson, Prof Coupland, Prof Clague, Dr Kalirai, Prof Field         £184,613 / three years 

 

Mechanistic investigation and risk: benefit analysis of the use of brusatol as a novel adjuvant for overcoming cisplatin resistance in bladder cancer

Dr Copple, Dr Hussain, Dr Goldring, Prof Park          £128,968 / two years 

 

The radiobiology of proton therapy

Dr Parsons         £186,096 / three years 

 

Development of novel multiplexable single-colour Ras GTPase sensors to compare spatio-temporal features of Ras signalling cascades with subcellular resolution

Dr Stagi, Prof Prior          £192,220 / three years 

 

Understanding the heterogeneity of chronic lymphocytic leukaemia through the elucidation of how genetic alterations influence protein expression at the whole genome level

Prof Pettitt, Dr Zhuang, Dr Kitteringham, Dr Jenkins, Prof Falciani, Prof Park          £194,420 / three years 

 

Phosphoproteomic analysis of the master centriole regulator Polo-like kinase 4 using target validated kinase inhibitors

Dr Patrick Eyers, Prof Claire Eyers, Dr Christopher Staples          £196,214 / three years 

 

S18‐phosphorylation controls catalytic activity of the cancer-associated deubiquitylase USP7: defining the implications for cancer biology and USP7 inhibitor therapy

Prof Judy Coulson, Dr Sarah Darling          £205,292 / three years

 

Investigating in-vivo resistance mechanisms to MEK inhibitors in uveal melanoma to enable novel combinatorial therapies

Dr Joseph Sacco, Prof Sarah Coupland, Dr Judy Coulson, Dr Patrick Eyers, Dr Helen Kalirai, Dr Sarah Lake          £131,189 / two years 

 

Gene edited reversal of FLT3-ITD mutations in acute myeloid leukaemia and its effect on chemotherapy resistance

Prof David J. MacEwan, Prof Richard E. Clark          £181,676 / three years 

 

The role of the ERK5 signalling axis in vemurafenib-resistant melanoma progression

Dr Cross, Mr Pritchard-Jones, Dr Tournier              £131,790 / two years 

 

Understanding the relationship between BCR signalling capacity and clonal behaviour in chronic lymphocytic leukaemia

Dr Kalakonda, Dr Slupsky, Prof Pettitt, Prof MacEwan, Prof Falciani          £195,288 / three years 

 

Novel therapeutic approches for personalised therapy of Head and Neck cancer 

Dr Shankar Varadarajan, Dr Joe Sacco, Dr Janet M Risk, Prof Gerald M Cohen          £192,243 / three years 

 

Evaluation of novel combination drug protocols for neuroblastoma using advanced imaging in a chick embryo model

Dr Violaine See, Prof Paul Losty          £117,382 / two years 

 

Forcing angiogenesis: Transcriptional control by integrin-dependent mechanotransduction during angiogenesis

Dr Mark Morgan, Dr Katarzyna Wolanska          £224,182 / three years 

 

Isolation and identification of the chromatin remodelling enzymes required for base excision repair

Dr Jason Parsons          £109,991 / three years 

 

Towards the clinical positioning of a first selective DUB inhibitor

Dr Sylvie Urbe, Prof Michael Clague, Dr Barry L Pizer, Dr Claire Heride          £141,569 / two years 

 

Non-canonical protein phosphorylation in human cancer cells

Prof Claire Eyers, Prof Pat Eyers, Dr Andrew Jones          £229,675 / three years 

 

Absolute quantitation of endogenous Ras isoform protein abundance: Does codon bias explain the predominance of KRAS mutations in cancer

Prof Ian Prior          £127,257 / two years 

 

Kinome profiling and mass cytometry as tools to detect rewiring of B cell receptor signalling in the malignant cells of chronic lymphocytic leukaemia patients taking ibrutinib

Dr J Slupsky, Prof Ian Prior          £217,307 / three years 

 

Integrating biomarkers to stratify adjuvant chemotherapy in pancreatic cancer patients

Dr William Greenhalf, Dr Dan Palmer, Dr Eithne Costello          £193,220 / three years 

 

Characterisation of the tumour- immune microenvironment in metastatic uveal melanoma

Dr Carlos Rogerio de Figueiredo, Prof Sarah Coupland            £132,434 / two years 

 

Function of stroma-derived gas6 in pancreatic cancer progression and metastasis

Dr Ainhoa Mielgo, Mr Robert Jones          £114,450 / three years 

 

Improving the biological response of proton beam therapy in head and neck cancer

Dr Jason Parsons          £202,129 / three years 

 

Tribbles pseudokinases: Analysis of cancer-associated signalling mechaniscHRISTIANMs

Prof Patrick Eyers, Dr Dominic Byrne, Prof Claire Eyers          £221,262 / three years 

 

The role of the ERK5 signalling axis in BRAF inhibitor-resistant melanoma progression

Dr Mike Cross, Dr Rowan Pritchard-Jones, Dr Cathy Tournier, Dr Emanuele Giurisato, Dr Harish Poptani, Prof Clare Eyers          £229,883 / three years 

 

Method optimisation of urine GC-MS analysis to predict dying in lung cancer patients

Dr Seamus Coyle, Professor John Ellershaw, Prof Chris Probert, Prof Mark Boyd          £33,899 / one year 

 

North West Cancer Research Centre 

The funding provides support for a Centre Administrator, a rolling PhD Studentship programme, the LCRIN Coordinator and support for the Research Development Fund. Funding was originally put in place in 2014 and this has now been extended through to the end of 2021.

£999,471 / four years